AdaptHealth (AHCO) | Financial Analysis & Statements
AdaptHealth Corp. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.5B
Gross Profit
795.8M
54.14%
Operating Income
34.1M
2.32%
Net Income
-101.5M
-6.91%
EPS (Diluted)
$-0.76
Balance Sheet Metrics
Total Assets
4.3B
Total Liabilities
2.8B
Shareholders Equity
1.5B
Debt to Equity
1.83
Cash Flow Metrics
Operating Cash Flow
41.6M
Free Cash Flow
79.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
AdaptHealth Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 3.3B | 3.2B | 3.0B | 2.5B |
| Cost of Goods Sold | 2.6B | 2.6B | 2.7B | 2.6B | 2.0B |
| Gross Profit | 609.2M | 681.1M | 479.6M | 417.4M | 445.6M |
| Gross Margin % | 18.8% | 20.9% | 15.0% | 14.1% | 18.2% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 382.3M | 359.2M | 190.1M | 162.1M | 167.5M |
| Other Operating Expenses | - | - | - | - | -10.6M |
| Total Operating Expenses | 382.3M | 359.2M | 190.1M | 162.1M | 156.9M |
| Operating Income | 186.3M | 276.8M | 232.4M | 190.4M | 225.6M |
| Operating Margin % | 5.7% | 8.5% | 7.3% | 6.4% | 9.2% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 105.8M | 126.7M | 130.3M | 109.4M | 95.2M |
| Other Non-Operating Income | -95.7M | -14.1M | -825.9M | 16.9M | 60.5M |
| Pre-tax Income | -15.2M | 136.0M | -723.8M | 97.9M | 191.0M |
| Income Tax | 50.9M | 41.2M | -49.0M | 24.8M | 32.8M |
| Effective Tax Rate % | 0.0% | 30.3% | 0.0% | 25.3% | 17.2% |
| Net Income | -66.0M | 94.8M | -674.8M | 73.1M | 158.2M |
| Net Margin % | -2.0% | 2.9% | -21.1% | 2.5% | 6.4% |
| Key Metrics | |||||
| EBITDA | 567.9M | 639.4M | 585.6M | 541.3M | 481.8M |
| EPS (Basic) | $-0.52 | $0.62 | $-5.06 | $0.47 | $1.12 |
| EPS (Diluted) | $-0.52 | $0.61 | $-5.31 | $0.33 | $0.67 |
| Basic Shares Outstanding | 135146000 | 133756000 | 134156000 | 134175000 | 126306000 |
| Diluted Shares Outstanding | 135146000 | 133756000 | 134156000 | 134175000 | 126306000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
AdaptHealth Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 106.1M | 109.7M | 77.1M | 46.3M | 149.6M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 370.9M | 408.0M | 388.9M | 359.1M | 359.9M |
| Inventory | 151.2M | 139.8M | 113.6M | 127.8M | 123.1M |
| Other Current Assets | 100.6M | 45.4M | 69.3M | 52.1M | 37.4M |
| Total Current Assets | 728.9M | 755.8M | 649.0M | 585.3M | 670.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.1B | 1.0B | 954.0M | 899.0M | 731.7M |
| Goodwill | 5.2B | 5.5B | 5.6B | 7.3B | 7.2B |
| Intangible Assets | 85.1M | 105.5M | 130.2M | 162.8M | 202.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 286.9M | 332.1M | 367.0M | 304.2M | 319.3M |
| Total Non-Current Assets | 3.6B | 3.7B | 3.9B | 4.6B | 4.6B |
| Total Assets | 4.3B | 4.5B | 4.5B | 5.2B | 5.3B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 352.4M | 284.6M | 211.5M | 222.5M | 248.0M |
| Short-term Debt | 68.7M | 60.5M | 91.8M | 67.2M | 66.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 30.1M | 33.5M | 14.7M | 19.9M | 43.2M |
| Total Current Liabilities | 712.4M | 567.0M | 537.0M | 456.2M | 499.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.8B | 2.1B | 2.2B | 2.3B | 2.3B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 243.8M | 272.0M | 302.1M | 305.5M | 322.5M |
| Total Non-Current Liabilities | 2.1B | 2.3B | 2.5B | 2.6B | 2.7B |
| Total Liabilities | 2.8B | 2.9B | 3.0B | 3.1B | 3.2B |
| Equity | |||||
| Common Stock | 13.0K | 13.0K | 13.0K | 13.0K | 13.0K |
| Retained Earnings | -633.0M | -562.2M | -652.6M | 26.3M | -43.0M |
| Treasury Stock | 25.5M | 25.5M | 43.3M | 14.0M | 0 |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.5B | 1.6B | 1.5B | 2.2B | 2.1B |
| Key Metrics | |||||
| Total Debt | 1.9B | 2.1B | 2.3B | 2.3B | 2.4B |
| Working Capital | 16.5M | 188.8M | 112.0M | 129.1M | 170.2M |
Balance Sheet Composition
AdaptHealth Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -66.0M | 94.8M | -674.8M | 73.1M | 158.2M |
| Depreciation & Amortization | 381.9M | 365.3M | 382.8M | 351.2M | 258.1M |
| Stock-Based Compensation | 21.9M | 14.9M | 22.5M | 22.4M | 25.3M |
| Working Capital Changes | 127.6M | -53.4M | -4.8M | -126.1M | -184.1M |
| Operating Cash Flow | 567.4M | 503.6M | -293.5M | 375.9M | 284.9M |
| Investing Activities | |||||
| Capital Expenditures | -382.4M | -306.1M | -337.5M | -391.4M | -203.3M |
| Acquisitions | 78.0M | -9.5M | -19.7M | -19.0M | -1.6B |
| Investment Purchases | 0 | 0 | -128.0K | -731.0K | -1.1M |
| Investment Sales | - | - | - | 0 | 0 |
| Investing Cash Flow | -303.2M | -310.3M | -357.3M | -411.2M | -1.8B |
| Financing Activities | |||||
| Share Repurchases | 0 | 0 | -29.3M | -14.0M | 0 |
| Dividends Paid | - | - | - | - | 0 |
| Debt Issuance | 0 | 253.5M | 50.0M | 0 | 2.3B |
| Debt Repayment | -268.5M | -433.3M | -101.8M | -36.2M | -869.4M |
| Financing Cash Flow | -303.4M | -200.7M | -95.1M | -70.2M | 1.6B |
| Free Cash Flow | 219.4M | 235.8M | 143.2M | -17.6M | 72.4M |
| Net Change in Cash | -39.1M | -7.4M | -746.0M | -105.5M | 45.5M |
Cash Flow Trend
AdaptHealth Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.64
Forward P/E
10.14
Price to Book
1.11
Price to Sales
0.53
PEG Ratio
-0.05
Profitability Ratios
Profit Margin
-2.18%
Operating Margin
6.20%
Return on Equity
-4.25%
Return on Assets
2.91%
Financial Health
Current Ratio
1.02
Debt to Equity
124.67
Beta
1.50
Per Share Data
EPS (TTM)
$-0.52
Book Value per Share
$11.46
Revenue per Share
$24.01
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AHCO | 1.7B | 16.64 | 1.11 | -4.25% | -2.18% | 124.67 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






